UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

              Current Report Pursuant to Section 13 or 15(d) of the
                        Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported) February 2, 2006

                         CALYPTE BIOMEDICAL CORPORATION
               (EXACT NAME OF COMPANY AS SPECIFIED IN ITS CHARTER)

      DELAWARE                        000-20985                  06-1226727
      --------                        ---------                  ----------
(STATE OR OTHER JURISDICTION)   (COMMISSION FILE NUMBER)      (I.R.S. EMPLOYER
   OF INCORPORATION)                   NUMBER)                  IDENTIFICATION)

             5 CENTERPOINTE DRIVE, SUITE 400, LAKE OSWEGO, OR 97035
             ------------------------------------------------------

               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282
                                                           --------------

                                       N/A

          (Former name or former address, if changed since last report)

|_|   Written communication pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 40.13e-4(c))


<PAGE>

ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
          STANDARD; TRANSFER OF LISTING.

On February 2, 2006 Calypte  Biomedical  Corporation (the "Company")  received a
letter from the American Stock Exchange (the  "Exchange")  notifying the Company
that it does not satisfy certain of the Exchange's  continued  listing standards
as set forth in Part 10 the American Stock Exchange  Company Guide (the "Company
Guide")  and that the  Exchange  staff has,  therefore,  determined  to initiate
delisting proceedings with respect to the Company's common stock.

Specifically,  the  Exchange  noted that the Company is not in  compliance  with
Section 1003(a)(i) with shareholders'  equity of less than $2,000,000 and losses
from continuing operations and/or net losses in two out of its three most recent
fiscal  years;  Section  1003(a)(ii)  with  shareholders'  equity  of less  than
$4,000,000 and losses from continuing  operations and/or net losses in three out
of its four most recent fiscal years;  Section  1003(a)(iii) with  shareholders'
equity of less than $6,000,000 and losses from continuing  operations and/or net
losses in its five most recent fiscal years; and Section 1003(a)(iv) with losses
which are so substantial  in relation to its overall  operations or its existing
financial  resources,  or its financial condition has become so impaired that it
appears questionable,  in the opinion of the Exchange, as to whether the Company
will be able to continue operations and/or meet its obligations as they mature.

The Company has until  February 10, 2006 to request an appeal of the  Exchange's
determination,  and  plans  to  request  a  hearing  before a  committee  of the
Exchange.  The Company expects that such a hearing would be scheduled  within 45
days of its request.  There can be no assurance  that the Company's  appeal will
result in the  continued  listing of its common  stock on the  Exchange.  If its
common stock is delisted  from the Exchange  after the hearing,  it would likely
trade on the NASD Over the Counter Bulletin Board.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1 Press release dated February 3, 2006

                                   SIGNATURES

Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date: Lake Oswego, Oregon
      February 3, 2006


                                        Calypte Biomedical Corporation


                                        By: /s/  Theodore R. Gwin
                                           -------------------------------------
                                                 Theodore R. Gwin
                                                 Chief Financial Officer
{"company-data": {"conformed-name": "CALYPTE BIOMEDICAL CORP", "cik": "0000899426", "assigned-sic": "3826", "irs-number": "061226727", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32280", "film-number": "06579267"}, "business-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588", "phone": "9257307200"}, "mail-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

              Current Report Pursuant to Section 13 or 15(d) of the
                        Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported) February 2, 2006

                         CALYPTE BIOMEDICAL CORPORATION
               (EXACT NAME OF COMPANY AS SPECIFIED IN ITS CHARTER)

      DELAWARE                        000-20985                  06-1226727
      --------                        ---------                  ----------
(STATE OR OTHER JURISDICTION)   (COMMISSION FILE NUMBER)      (I.R.S. EMPLOYER
   OF INCORPORATION)                   NUMBER)                  IDENTIFICATION)

             5 CENTERPOINTE DRIVE, SUITE 400, LAKE OSWEGO, OR 97035
             ------------------------------------------------------

               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282
                                                           --------------

                                       N/A

          (Former name or former address, if changed since last report)

|_|   Written communication pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 40.13e-4(c))
ITEM 3.01 NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
          STANDARD; TRANSFER OF LISTING.

On February 2, 2006 Calypte  Biomedical  Corporation (the "Company")  received a
letter from the American Stock Exchange (the  "Exchange")  notifying the Company
that it does not satisfy certain of the Exchange's  continued  listing standards
as set forth in Part 10 the American Stock Exchange  Company Guide (the "Company
Guide")  and that the  Exchange  staff has,  therefore,  determined  to initiate
delisting proceedings with respect to the Company's common stock.

Specifically,  the  Exchange  noted that the Company is not in  compliance  with
Section 1003(a)(i) with shareholders'  equity of less than $2,000,000 and losses
from continuing operations and/or net losses in two out of its three most recent
fiscal  years;  Section  1003(a)(ii)  with  shareholders'  equity  of less  than
$4,000,000 and losses from continuing  operations and/or net losses in three out
of its four most recent fiscal years;  Section  1003(a)(iii) with  shareholders'
equity of less than $6,000,000 and losses from continuing  operations and/or net
losses in its five most recent fiscal years; and Section 1003(a)(iv) with losses
which are so substantial  in relation to its overall  operations or its existing
financial  resources,  or its financial condition has become so impaired that it
appears questionable,  in the opinion of the Exchange, as to whether the Company
will be able to continue operations and/or meet its obligations as they mature.

The Company has until  February 10, 2006 to request an appeal of the  Exchange's
determination,  and  plans  to  request  a  hearing  before a  committee  of the
Exchange.  The Company expects that such a hearing would be scheduled  within 45
days of its request.  There can be no assurance  that the Company's  appeal will
result in the  continued  listing of its common  stock on the  Exchange.  If its
common stock is delisted  from the Exchange  after the hearing,  it would likely
trade on the NASD Over the Counter Bulletin Board.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1 Press release dated February 3, 2006

                                   SIGNATURES

Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date: Lake Oswego, Oregon
      February 3, 2006

                                        Calypte Biomedical Corporation

                                        By: /s/  Theodore R. Gwin
                                           -------------------------------------
                                                 Theodore R. Gwin
                                                 Chief Financial Officer